Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 93 of 121 for:    ZOLPIDEM AND Central Nervous System Depressants

Safety and Efficacy of Chronic Hypnotic Use 2 (CIS2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02456532
Recruitment Status : Recruiting
First Posted : May 28, 2015
Last Update Posted : August 9, 2018
Sponsor:
Information provided by (Responsible Party):
Timothy Roehrs, PhD, Henry Ford Health System

Brief Summary:
This proposal will assess risks for transition from therapeutic hypnotic use to abuse in people with insomnia. The investigators will study a hypothesized at-risk sub-population, insomniacs with hyperarousal, and compare two hypnotics, a drug with mood effects, eszopiclone, versus one without mood effects, zolpidem.

Condition or disease Intervention/treatment Phase
Chronic Insomnia Drug: placebo Drug: Zolpidem CR Drug: Eszopiclone Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Risks for Transition From Therapeutic Hypnotic Use to Abuse
Study Start Date : July 2015
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Intervention: Six months of nightly placebo
Drug: placebo
Active Comparator: Zolpidem CR
Intervention: Six months of zolpidem cr 12.5 mg nightly use
Drug: Zolpidem CR
Active Comparator: Eszopiclone
Intervention: Six months of eszopiclone 3 mg nightly use
Drug: Eszopiclone



Primary Outcome Measures :
  1. change in number capsules chosen: nightly choice of 0, 1, 2, or 3 capsules [ Time Frame: last two weeks of month1 and 3 ]
    total possible nightly dose limited to upper clinical dose

  2. discontinuation difficulty: nightly choice of 0, 1, 2, or 3 capsules [ Time Frame: last two weeks of month 6 ]
    instruction to stop nightly hypnotic use


Secondary Outcome Measures :
  1. change in actigraphic determined sleep time [ Time Frame: first two weeks of months 1, 3, and 6 ]
    comparing the three treatment arms for hypnotic efficacy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • DSM-5 diagnosis of insomnia

Exclusion Criteria:

  • acute or unstable medical disease,
  • current or past history of psychiatric disease, alcoholism or drug abuse, and other primary sleep disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02456532


Contacts
Layout table for location contacts
Contact: Gail Koshorek, BS 313-916-5179 gkoshor1@hfhs.org

Locations
Layout table for location information
United States, Michigan
HFHS Sleep Disorders Ctr Recruiting
Detroit, Michigan, United States, 48202
Contact: Gail Koshorek, BS    313-916-5179    gkoshor1@hfhs.org   
Contact: Dana Withrow, MHA    313-916-5302    dwithro2@hfhs.org   
Sponsors and Collaborators
Henry Ford Health System
Investigators
Layout table for investigator information
Principal Investigator: Timothy A Roehrs, PhD Henry Ford Health System Sleep Disorders Ctr

Layout table for additonal information
Responsible Party: Timothy Roehrs, PhD, Senior Bioscientist, Henry Ford Health System
ClinicalTrials.gov Identifier: NCT02456532     History of Changes
Other Study ID Numbers: #9384
First Posted: May 28, 2015    Key Record Dates
Last Update Posted: August 9, 2018
Last Verified: August 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Diseases
Zolpidem
Central Nervous System Depressants
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Mental Disorders
Eszopiclone
Hypnotics and Sedatives
Sleep Aids, Pharmaceutical
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action